Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • AI Tools
  • Multichannel Amplification
  • Guaranteed Paid Placement
  • SocialBoost
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Overview
  • Distribution by PR Newswire
  • AI Tools
  • Multichannel Amplification
  • SocialBoost
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

REVIVAL HEALTH MEDICAL SUPPLY INC. AWARDED EXCLUSIVE MASTER DISTRIBUTORSHIP IN THE U.S. FOR THE BOSON™ RAPID SARS-COV-2 ANTIGEN TEST

Revival Health Medical Supply Inc (Revival Health), a health tech and medical supply company and U.S. Department of Defense contract awardee.

News provided by

Revival Health Medical, Inc.

May 05, 2022, 06:00 ET

Share this article

Share toX

Share this article

Share toX

FDA Emergency Use Authorized Boson™ Rapid SARS-CoV-2 Antigen Test, Colloidal Gold, Exclusively Available from Revival Health Medical Supply, Inc.

Revival Health Committed to Transparency, Standardized Operating Process and Elimination of Grey Market Counterfeit Product.

MANHATTAN BEACH, Calif., May 5, 2022 /PRNewswire/ -- Revival Health Medical Supply, Inc. (Revival Health), a health tech, medical supply company and Department of Defense contract awardee and Xiamen Boson Biotech Co., Ltd. (Boson), a global developer and manufacturer of high-quality lateral flow immunoassay kits, announced today a joint agreement that awards Revival Health as the exclusive distributor of the Boson™ Rapid SARS-CoV-2 Antigen Tests with sole authorization to sell in or to the U.S.  The partnership comes just weeks after the Boson™ Rapid SARS-CoV-2 Antigen Test received Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA).

Continue Reading
Boson™ Rapid SARS-CoV-2 Antigen Test
Boson™ Rapid SARS-CoV-2 Antigen Test

The strategic partnership is committed to transforming the test kit industry by offering a reliable distribution solution to eliminate price gouging and fluctuation, counterfeit and bootleg products and multiple unauthorized sales channels. As a matter of public safety, Revival Health is committed to ending the grey market for COVID tests by implementing its 8-Point Plan:

  1. A single Standardized Operating Procedure for purchase of product.
  2. Inspection and delivery through 10 authorized warehouses, nationwide.
  3. Enabling a network of authorized federal inspectors for product inspection and verification.
  4. Implementation of a real-time product tracking and authenticity solution.
  5. Elimination of sales through unauthorized distributors and warehouses.
  6. Elimination of "direct" from China sales.
  7. Standardized pricing and penalizing low price distributors and sellers.
  8. Working closely with state Attorney General offices and the FDA to prosecute offenders wherever possible. Prosecution for trademark and copyright infringement for counterfeiters and bootleggers.

Eliminating the grey market for Boson goods will enhance public safety, ensure high quality and dependability of product and accuracy of information, and end fluctuating pricing.

"As a leading specialist of in vitro diagnostic kits, we value our ability to provide high quality rapid tests efficiently and cost effectively. Fraudulent activity diminishes the value and integrity of the Boson brand. We believe awarding Revival Health with master distributorship helps eliminate counterfeit and bootlegged Boson products, ensuring our end users that they are always using authentic Boson products," said Changgong Zhang, General Manager of Boson.

"During these times of high demand, many COVID test providers and distributors like ourselves have discovered fraudulent activity that risks the integrity of these tests. We are committed to a transparent selling process, one by which we publicize wholesale prices weekly, distribute product through ten official warehouses and keep Boson tests within a standardized supply chain so that customers can easily identify unofficial product and false claims," said Robb Fujioka, Revival Health CEO. "Without making clear and bold moves to control the import and sales of counterfeit product, ultimately the end consumers—families and employees—pay the price by getting fake, unreliable tests. We are committed to doing our part to help drive change."
 

The Boson™ Rapid SARS-CoV-2 Antigen Test Card is an immunochromatography-based one step in vitro test. It is designed for the rapid qualitative determination of SARS-CoV-2 virus antigen through anterior nasal swabs within the first six days of symptom onset.

Boson Rapid CARS-CoV-2 Antigen Test Intended Uses:

  • At-home COVID-19 antigen diagnostic test that shows results in 15 minutes.
  • Intended for use as a serial test for people with or without symptoms, meaning the test is done two times over three days, with at least 24 hours but no more than 48 hours between tests.
  • Can be used for people ages 14 years or older with a self-collected nasal swab sample, or ages 2 years or older when an adult collects the nasal swab sample.

The tests are available immediately as two tests per box with 1,4,5,8,20, and 40 test boxes available to order.

About Revival Health Medical Supply, Inc.
Revival Health Medical Supply was founded to solve healthcare's biggest problem— How to deliver preventative care, early. Our mission is to make home healthcare and preventative medicine affordable, accessible, and easy to use. Our platform is uniquely designed to offer a robust ecosystem of hardware (testing, monitoring, and wearables), software (tracking and analytics and EHR/EMR) and services (telemedicine and e-pharmacy) to empower everyone to lead longer, healthier lives by predicting disease onset and delivering treatment earlier.

We prioritize simplicity so that our technology is accessible to everyone. Early in development, it became clear that home health care was highly fragmented and often siloed across multiple departments and therapeutic areas. As such, we set out to build a comprehensive solution that combines home testing, monitoring, telemedicine and e-prescribe backed by a health dashboard and Electronic Health Records access for an easy to use and adopt unified solution. For more information, visit www.revival.care.

About Xiamen Boson Biotech Co., Ltd.
Xiamen Boson Biotech Co., Ltd., as a specialist of in vitro diagnostic kits founded in 2001, develops and manufactures high-quality point of care and other immunoassay kits for the worldwide market. Our 12,500 square meter facility is operated strictly under ISO 13485:2016 and GMP guidelines. We combine the technological, material and labor resources of China and the U.S. to develop, manufacture and supply high quality in vitro diagnostic products efficiently and cost effectively. Currently, we are offering product lines of rapid tests, CLIA, and raw materials. These product lines provide immunoassays in various formats to detect cardiac markers, drugs of abuse, fertility hormones, infectious diseases, tumor markers and animal diseases. Many of our products have been approved by the China NMPA. Xiamen Boson Biotech's mission is to provide affordable high-quality products to help fight diseases and illicit substance abuse.

MEDIA CONTACT:
Lisa Fujioka
[email protected]

SOURCE Revival Health Medical, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.